Year Founded
2015
Ownership
Private
Employees
~10
Stage
Preclinical
Modalities
Small molecule

SigmaDrugs General Information

Company is developing treatments for fibrotic diseases and organ preservation, with lead compound showing promising results in bleomycin-induced pulmonary fibrosis mouse model

Contact Information

Website
Primary Industry
Biotech
Corporate Office
Budapest,
Hungary

Drug Pipeline

Pre-clinical
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum
Drug Asset 2
Phase X
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum
Drug Asset 3
Phase X
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum

For full access to SigmaDrugs's pipeline data

Book a demo

Key Partnerships

Need more data on over 80,000 life science companies, including over 1200 biotechs?

Book a demo

SigmaDrugs Funding

No funding data available

Early Stage VC (Series A)04-Jun-2020$38MCompletedPhase 1
Seed Round12-Feb-2019$8.5MCompletedStartup

Interested in comprehensive profile data?

We'll help you find what you need

Learn more
To view SigmaDrugs's complete valuation and funding history, request access »